Lucentis Biosimilar

Jul 22, 2022

Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landscape changed the market once dominated by Roche.Moving forward, RVO’s robust pipeline, along with several VEGF inhibitors, creates trouble for the big ones; Lucentis and Eylea. Retinal vein occlusion is the second most common s...

Dec 22, 2021

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a compelling economic value proposition. This has been a considerable element in expanding the biosimilar market, and the future of this sector appears promising. Many pharmaceutical companies from across the globe are proactively...

Dec 15, 2021

Since the first biosimilar drug was approved in 2006, the EU has led the way in biosimilar regulation. Over the last decade, the EU has authorized the most biosimilars globally, gathering significant expertise with their usage and safety. Over ten years of clinical experience has shown that biosimilars licensed by ...

Dec 03, 2021

The expiration of many biologic drugs patents has sparked biosimilar development and boosted the biosimilar market growth. Biosimilars are alternative versions of innovator biologic drugs. These are biological products that are similar replicas of the biopharmaceuticals that inspired them. Biosimilars are sometimes...

Aug 19, 2016

Zymeworks licenses new drug discovery platform from Innovative Targeting Solutions Zymeworks, a biotech company working on bispecific antibodies, has signed a licensing deal with Innovative Targeting Solutions (ITS) for HuTARG, which works as a protein engineering platform, and is the first fully mammalian tech that...